Pay in 4 interest-free payments of $6.23 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
Due to the concern about the growing prevalence of unapproved GLP-1s on the market, the FDA issued warning letters to the following companies in December: The FDA warned the companies about potential violations of the Federal Food, Drug, and Cosmetic Act (FD&C Act), even with the companies claiming some of their GLP-1 products were currently for research purposes only
The most powerful tool you have is plan choice
Major airlines are hopeful to save on weight-related fuel costs, and insurance companies are grappling with the decision to cover these costly drugs
Generics can be expected in Canada in 2026, and in the US, most likely in the early 2030s
Therefore, this study aimed to characterize the real-world cardiovascular adverse event reporting profile of tirzepatide using the FAERS database from 2022 to 2025
US$ 22.29
US$ 25.56
US$ 21.26
US$ 21.62
US$ 26.11
